A diagnostic device in an electrical interferential treatment regime applies different pulse frequencies in one selection of electrode placement and determines the change of blood flow in response to the change in pulse frequency in an attempt to determine an optimum or workable set of parameters. The device includes electronic storage to record a series of tests and their results and a communication link. The communication link enables a professional caregiver to determine whether the parameter determinations, made at a location remote from the professional's office, such as at the residence of the patient, were conducted and were conducted correctly. The communication link also enables the professional to determine whether the treatments were conducted and conducted correctly.
|
1. A system for determining and applying treatment parameters for a trial electrical interferential treatment regimen conducted on a patient situated at a first location, comprising:
pairs of electrodes adapted for external temporary attachment, respectively, to opposite limbs of a patient situated at said first location and at least one electronic device at said first location for delivering a series of trial electrical interferential treatments to the patient through the electrodes, and, for a pair of electrode placements, each electrical interferential treatment comprises electrical interferential treatment parameters of at least one beat frequency;
a sensor configured to measure at least one biological function responsive to autonomic nervous system activity of the patient caused by each electrical interferential treatment parameter delivered;
said at least one electronic device responsive to said sensor and adapted to convert the at least one measured biological function to a numerical value;
said at least one electronic device further adapted to compare said numerical value to a predetermined numerical value indicative of a desired biological function;
said at least one electronic device further adapted to store data of said numerical values, said treatment parameters of said series of trial electrical interferential treatments and said treatment parameters of said at least one electrical interferential treatment that corresponds to a numerical value that is in excess of said predetermined numerical value;
said at least one electronic device further adapted to electronically transmit said stored data to at least one other electronic device situated at a second location away from the immediate vicinity of the first location;
said at least one electronic device further adapted to allow selection of said treatment parameters of the at least one electrical interferential treatment that produced said numerical value in excess of the predetermined value and apply the selected treatment parameters through the electrodes to the patient in a subsequent selected treatment regimen;
said at least one electronic device being adapted for viewing said numerical values; and
said at least one other electronic device being adapted for viewing said numerical values, said treatment parameters of said series of trial electrical interferential treatments and said treatment parameters of said identified electrical interferential treatment that produced said numerical value in excess of the predetermined value and determining from said stored data whether said treatment parameters of said identified electrical interferential treatment produced a numerical value in excess of the predetermined value.
3. The system of
4. The system of
5. The system of
|
This application is based on Provisional Patent Application Ser. No. 61/744,085, filed Sep. 17, 2012, and U.S. patent application Ser. No. 13/987,897 filed Sep. 13, 2013, now U.S. Pat. No. 9,061,145, priority of which is claimed.
This invention relates to a method and apparatus for determining effective treatment parameters in an electrical interferential system.
U.S. patent application Ser. No. 11/374,903, filed Mar. 14, 2006, now U.S. Pat. No. 9,061,145, the disclosure of which is incorporated herein by reference, discloses a technique for determining better treatment parameters for an electrical interferential treatment by delivering various pulses and electrode locations and measuring the patient's response to the applied treatment. By varying these parameters and exercising experienced judgment, an effective set of parameters is obtained for treating the ailment presented by the patient.
Disclosures of some interest relative to this invention are found in U.S. Pat. Nos. 4,505,275; 6,016,447; 6,154,675; 6,698,921 and U.S. Printed Patent Applications 20020003832; 20070150029; 20100063564; 20100106226; 20100211135; 20100222844; 20110105916; 20110106216; 20110152974; 20110231836 and 20110313488.
In an attempt to obtain more efficient treatment parameters, shorten the time to determine these parameters, require less experienced personnel and rely on patients or their caregivers to determine effective parameters, the responses of the patient may be entered into software designed to obtain better parameters. The software may contain a series of logic circuits which may be briefly described as an effort to determine whether the patient experiences improved blood flow in response to the application of a series of treatment parameters.
One broad manner of intended use of the disclosed technique is for the patient to be initially treated by professionals in a professional setting where a first set of treatment parameters is obtained and a first treatment delivered to the patient. Many subsequent treatments may be conducted by the patient or caregiver at a location other than a professional office, such as at the patient's residence. In order to run subsequent treatments, a new set of treatment parameters may preferably be obtained by the device using the same device and software.
The hardware and software obtain, in an automated way, the patient's response to a series of treatment parameters and saves or stores the patient's responses to the parameters, typically on an electronic storage medium, along with the parameters, the time and manner the parameters were determined and other pertinent information. Similarly, the time and parameters used in a treatment may also be saved or stored. A communications link may be provided to allow a professional to check on whether the treatment parameters were selected in an appropriate manner. Similarly, the communications link may be used to allow a professional to check on whether the treatments were in fact done and done in a manner and at a time consistent with best practice.
In the practice of the disclosed technique, electrical energy in the form of electrical interferential pulses are delivered into the patient's body. These treatments cause change in the patient which is monitored by the disclosed device. In other words, the effect of the electrical interferential pulses is monitored by one or more sensors that detect a function or an aspect of the autonomic nervous system. The sensed changes in the patient are then used to modify the output of the treatment unit and/or the placement of the electrodes used by the treatment machine. In other words, the results of the tests are used in an attempt to determine a preferred way to treat the patient by adjusting the treatment machine in response to the tests results.
A healthy organism is capable of quickly adjusting to many external influences because of an adequate sympathetic response. Once that factor disappears, parasympathetic activity increases, which balances overall autonomic activity. It has become known that a large majority of people have overly active sympathetic nervous systems, i.e. their sympathetic nervous systems are overpowering or dominating their parasympathetic nervous system. This may have many effects, some of which may be controversial although many are not. In general, an overly active sympathetic nervous system tends to create or accentuate such diverse conditions or ailments such as diabetes type 1 and type 2, fibromyalgia, bipolar disorder, endometriosis, hypertension and other ailments such as disclosed in application Ser. No. 11/326,230, filed Jan. 5, 2006 or those ailments disclosed in U.S. Pat. No. 5,995,873.
A wide variety of techniques may be used to monitor the autonomic nervous system and thereby determine the effect of an interferential treatment on the patient. A preferred technique is to monitor finger tip temperature because the response is relatively rapid, easy to measure and is relatively unambiguous. In the alternative, or in addition, to monitoring finger tip temperature, other manifestations of the autonomic nervous system may be monitored, for example, skin resistivity, pulse rate, blood pressure, iris pupil diameter, respiration rate, or any other indicator of autonomic nervous system function.
Referring to
The housing 14 may include a pair of receptacles 32, 34 capable of accepting a jack 36, 38 of insulated wire pairs 40, 42 leading to electrode pairs 44, 44′ and 46, 46′. A suitable display 48 provides readings such as values from the sensors 18, 20, the carrier frequency, the pulse frequency being tested, the time and date of the procedure and any other desirable information, such as the intensity of treatment, time left to finish the treatment, time elapsed during a particular testing cycle, results of testing sequences, and whether it is time to replace the electrodes.
Standard commercially available electrical interference treatment devices have either a fixed carrier frequency or a minimally selective carrier frequency. For reasons which are mainly historical, these frequencies are conventionally 1850 Hz and 2850 Hz in the Sympathetic Therapy System from Dynatronics, Inc. and 4000 Hz in a device commercially available by Rehabilicare Corporation of St. Paul, Minn. In this device, the carrier frequency may be either fixed or variable.
The device 12 may include a select actuator 50 and up/down actuators 52, 54. It is sometimes desirable to increase the intensity of the electrical pulses. Assuming the actuator 52 to increase intensity, it may be manually depressed and an intensity value may be displayed on the screen 48. When the desired intensity value shows on the screen 48, the select actuator 50 may be depressed to instruct the module 28 to increase the intensity to the selected value. The module 28 may provide other functions. For example, the electrodes 44, 44′, 46, 46′ don't provide good sensings indefinitely. The module 28 may run tests to determine whether the electrodes need to be replaced, may count the number of treatments or the number of parameter determining trials are run and display a message on the screen 48 to replace the electrodes. In response to such a message, the select actuator 50 may be depressed to send a message to the module 28 that the electrodes have been or will be changed. The device 12 may also include a timer function and the time of and duration of treatments and/or the acquisition of treatment parameters. The device 12 may also include an on-off switch 56.
The carrier and beat frequencies used in selecting treatment parameters may be selected by the actuators 50, 52, 54 or default selections may be provided by software in the processor 28. Experience has shown that the vast majority of desirable beat frequencies are between 1-150 beats per second (bps) although current commercially available devices only employ 1-80 beats per second. In attempts to find the most desirable beat frequency in a reasonable time frame, this range has been subdivided into smaller segments. Experience has shown that some of the segments, at least at one carrier frequency where most efforts have been made, provide the most desirable beat frequency.
When it is desired to increase the treatment intensity, the increase actuator 52 is depressed. When it is desired to decrease the treatment intensity, the decrease actuator 54 is depressed. It will accordingly be seen that the device 12 includes a circuit for delivering therapeutic electrical energy into the body of the patient and more particularly includes a subcircuit for modifying the carrier frequency, the beat frequency and/or the amplitude of alternating current type energy.
The first thing that may be done is to allow or insure that the finger tip temperature of the patient has stabilized. The patient's finger temperatures often change in response to room temperature and it may be desirable to allow them to cease responding to room temperature. This may be done by measuring the initial temperature of the patient's finger tips and determining whether the temperature is varying over time. At the end of a short specified period, e.g. one minute, a determination is made whether finger tip temperature has stabilized by comparing initial and subsequent temperatures. A suitable set of parameters is that when finger tip temperature changes less than 1° F. in one minute, the processor 28 determines that temperature has stabilized and the acquisition of treatment parameters continues in accordance with
The electrodes are attached to the patient's skin in a conventional manner, i.e. they may be self adherent. The location of the electrodes on the patient establish the electrical circuit in the patient's body. As shown in
The electrode pattern illustrated in
Those skilled in the art will recognize that the terminus of the right medial plantar nerve L5 is located on the bottom of the right foot, approximately on the ball of the foot. The terminus of the left sural nerve S1 is located below the left ankle bone (lateral malleolus). Another electrode 46 is placed adjacent the terminus of the right sural nerve S1 and its matching electrode or mate 46′ is placed adjacent the terminus of the left medial plantar nerve L5 thereby establishing a second circuit 60 in the patient's body. Turning the device 12 on delivers electrical energy through the circuits 58, 60. Those skilled in the art will recognize that the medial plantar nerves L5 and the sural nerves S1 terminate adjacent the spinal column near adjacent spinal vertebra, in the area of the connection to the lumbar sympathetic ganglia.
Other arrangements of the electrodes to stimulate other nerves are within the scope of this invention and are shown in U.S. Pat. No. 5,995,873. There are several thousand potential electrode arrangements so it is desirable to start the acquisition of treatment parameters by selecting one arrangement that experience has shown to often produce effective treatments.
Referring to
Initially, the patient is briefly subjected to no carrier frequency or frequencies or beat frequency or frequencies for a short period, typically about five minutes, in order to allow the thermistors to equilibrate to the finger temperature. Then, the patient is subjected to a series of tests, initially using different beat frequencies in an attempt to determine an effective, optimum or ideal combination of parameters that produce a desired effect on the autonomic nervous system and thereby determine a preferred treatment regimen. This may be accomplished by using one of the carrier frequencies and delivering a series of pulses in a first range, such as 1-10 pulses/second, while sensing and recording the temperature measured by the sensors 18, 20. The sequence of delivering the pulses may be in any suitable manner. The standard interferential module 16 produces a sweep of beats in this range in the following repeating pattern: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, changing every second. The finger tip temperature may be recorded continuously or at any suitable interval, e.g. one minute. A hypothetical temperature pattern conducted on a female having an original left finger tip temperature of 71.2° F. and an original right finger tip temperature of 72.6° F. is shown in Table I:
TABLE I
left
right
finger
finger
average
initial
71.2° F.
72.6° F.
71.9° F.
end of 1 min
71.6° F.
72.8° F.
72.2° F.
end of 2 min
71.6° F.
72.8° F.
72.2° F.
end of 3 min
71.6° F.
72.6° F.
72.1° F.
The purpose of the trial is to determine parameters that produce a significant increase in digit temperature based on the premise that this is a proxy for improved blood circulation. Table I shows a situation where the subject's finger tip temperature increased about 0.4° F. in three minutes. This suggests a minimal increase in blood circulation so software in the processor module 28 concludes the selected pulse beat frequency and electrode placement is ineffective.
The module 28 accordingly writes onto the memory module 30 information relevant to the trial, e.g. the serial number of the device 12, the time and date of the trial, and all of the data created during the testing and running of the treatment onto the memory module 30.
If the temperature response from the first trial is not satisfactory, as in Table I, which may be where the digit temperature increase is less than 1° F., then a second trial may commence using a different pulse frequency, e.g. 11-20 beats per second. This process repeats until a temperature increase above some minimum, which is preferably at least 1° F. in a few minutes such as three or four minutes, is attained or until some maximum range is reached. If there is no successful trial after trying each ten pulse range through the maximum range, a message appears on the display 48 to try a different electrode pattern and/or a different carrier frequency. The process is repeated until a satisfactory temperature increase is obtained. All of the trial parameters and trial results are written onto the memory module 30.
Following a successful trial that determines parameters suggesting substantially improved blood flow, i.e. the temperature response is above a predetermined threshold such as a 1° F. temperature rise in a few minutes, the selected treatment may be delivered to the patient in response to a message on the display 48 or automatically. The patient, caregiver or professional may instruct the device 12 to apply the treatment by depressing the select actuator 50. If, having tested all of the beat frequency permutations available, no combination is able to create an adequate thermistor temperature increase indicating an adequate circulation increase, the beat frequency combination which created the highest increase will be utilized for the treatment. At the end of the treatment, a message appears on the display 48 saying “new protocol needed” or other similar message advising the clinician or patient that a different electrode placement is needed. In the alternative, in a situation where the patient or caregiver is conducting these trials at a location remote from the professional's premises, the message may indicate that the professional be contacted to determine another electrode pattern or that a reference book or data base be used to determine another electrode pattern.
The memory module 30 provides an important advantage. There are situations where the patient or patient's caregiver is conducting trials to determine suitable parameters and then delivering treatments at a location away from the professional's office, e.g. at the patient's residence. In this situation, it is very desirable to have the capability of reviewing the trial procedures and results. In the case of a removable memory module, the module 30 may be removed and placed in a computer 68 where data from the module 30 may be transmitted through a communication link 70 to the professional's office 72 where the data can be stored on a computer 74, retrieved and viewed (
The communication link 70 also allows the professional to review whether, when and how treatments were conducted because treatment information, as well as parameter acquisition information, is written onto and stored on the memory module 30. Thus, treatment information as well as parameter information may be transmitted to the professional.
Referring to
Although this invention has been disclosed and described in its preferred forms with a certain degree of particularity, it is understood that the present disclosure of the preferred forms is only by way of example and that numerous changes in the details of operation and in the combination and arrangement of parts may be resorted to without departing from the spirit and scope of the invention as hereinafter claimed.
Patent | Priority | Assignee | Title |
11517753, | Feb 20 2020 | Interferential treatment with modified beat frequency |
Patent | Priority | Assignee | Title |
4505275, | Sep 15 1977 | Treatment method and instrumentation system | |
5211479, | Jan 13 1992 | Digital pacifier thermometer | |
5995873, | Jul 07 1998 | Treatment of pain and of the nervous system | |
6016447, | Oct 27 1998 | Medtronic, Inc | Pacemaker implant recognition |
6154675, | Oct 27 1998 | Medtronic, Inc | Resetting ERI/POR/PIR/indicators in implantable medical devices |
6650944, | Feb 23 2000 | Medtronic, Inc.; Medtronic, Inc | Follow-up monitoring method and system for implantable medical devices |
6698921, | May 18 1999 | CAREFUSION 303, INC | Predictive temperature measurement system |
6826429, | Jan 19 2001 | Alan Neuromedical Technologies, LLC | Interferential current treatment apparatus |
7329044, | Jun 04 2001 | OMRON HEALTHCARE CO , LTD | Infrared clinical thermometer and temperature state estimation method, information notification method, and measurement operation method thereof |
20020003832, | |||
20070150029, | |||
20070173727, | |||
20100063564, | |||
20100106226, | |||
20100211135, | |||
20100222844, | |||
20110105916, | |||
20110106216, | |||
20110152974, | |||
20110238136, | |||
20110313488, | |||
20120226197, | |||
20120277621, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Date | Maintenance Fee Events |
Sep 09 2019 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
Sep 18 2023 | M2552: Payment of Maintenance Fee, 8th Yr, Small Entity. |
Date | Maintenance Schedule |
May 10 2019 | 4 years fee payment window open |
Nov 10 2019 | 6 months grace period start (w surcharge) |
May 10 2020 | patent expiry (for year 4) |
May 10 2022 | 2 years to revive unintentionally abandoned end. (for year 4) |
May 10 2023 | 8 years fee payment window open |
Nov 10 2023 | 6 months grace period start (w surcharge) |
May 10 2024 | patent expiry (for year 8) |
May 10 2026 | 2 years to revive unintentionally abandoned end. (for year 8) |
May 10 2027 | 12 years fee payment window open |
Nov 10 2027 | 6 months grace period start (w surcharge) |
May 10 2028 | patent expiry (for year 12) |
May 10 2030 | 2 years to revive unintentionally abandoned end. (for year 12) |